A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Hemispherx BioPharma Inc (AMEX: HEB) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on August 21, 2015 and AMEX: HEB investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 08/17/2015 -- A deadline is coming up on August 21, 2015 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Hemispherx BioPharma Inc (AMEX: HEB) between March 14, 2012 and December 20, 2012.
Investors who purchased a significant amount of shares of Hemispherx BioPharma Inc (AMEX: HEB) between March 14, 2012 and December 20, 2012, have certain options and should contact the Shareholders Foundation by email at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Hemispherx BioPharma Inc (AMEX: HEB) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/hemispherx-biopharma-inc-amex-heb-investor-securities-class-action-lawsuit-12212012
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is August 21, 2015. The class action administrator for this case is KCC Class Action Services.
The lawsuit was originally filed in the U.S. District Court for the Eastern District of Pennsylvania against Hemispherx BioPharma Inc over alleged securities laws violations of Federal Securities Laws in connection with certain allegedly false and misleading statements concerning Hemispherx BioPharma Inc's new drug Ampligen. According to the complaint the plaintiff alleges on behalf of all persons or entities who purchased or otherwise acquired securities of Hemispherx BioPharma Inc (AMEX: HEB) between March 19, 2012 and December 17, 2012, that Hemispherx BioPharma Inc and certain of its officers and directors violated the Securities Exchange Act of 1934 by assuming between March 19, 2012 and December 17, 2012 allegedly false and misleading information about its lead drug candidate Ampligen.
Hemispherx BioPharma Inc, located in Philadelphia, PA is a biopharmaceutical company that is engaged in the clinical development of new, natural immune system enhancing drug therapies based on the treatment of viral and immune based chronic disorders in the United States.
Those who purchased shares of Hemispherx BioPharma Inc (AMEX: HEB) have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com